Should Inovio's Lawsuits Worry Investors?
Inovio Pharmaceuticals (NASDAQ: INO) has been around for nearly 40 years. It's probably fair to say, though, that the small biotech has never enjoyed as much attention as it's received so far in 2020.
COVID-19 caused major problems for many companies. The pandemic turned out to be a huge catalyst for Inovio, however, after the biotech began developing a vaccine candidate for potential immunization against SARS-CoV-2, the novel coronavirus that causes COVID-19.
But Inovio does face some problems. In particular, the biotech now faces high-profile legal disputes. Should investors be worried about Inovio's lawsuits?
Source Fool.com
